natgillin/translations-raw huggingface dataset:
Haemodialysis shortly after VASOVIST administration in patients currently receiving haemodialysis may be useful at removing VASOVIST from the body.
Pri bolnikih zdravljenih s hemodializo je lahko hemodializa izvedena kmalu po uporabi kontrastnega sredstva VASOVIST koristna za njegovo odstranitev iz telesa.
VASOVIST is supplied ready to use as a clear, colourless to pale yellow aqueous solution.
VASOVIST je na voljo v obliki pripravljene, bistre, brezbarvne do svetlo rumene vodne raztopine.
After withdrawal of the solution from the vial, this medicinal product should be used immediately.
Po odvzemu raztopine iz viale morate kontrastno sredstvo uporabiti takoj.
If you need more information about your medical condition or your treatment, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Če potrebujete več podatkov o svojem zdravstvenem stanju ali zdravljenju, preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
If you want more information on the basis of the CHMP recommendations, read the Scientific Discussion (also part of the EPAR).
Če želite več podatkov, ki temeljijo na priporočilih (CHMP), preberite znanstveno razpravo (ki je prav tako del EPAR).
Vectibix is a concentrate that is made up into a solution for infusion (drip into a vein).
Zdravilo Vectibix je koncentrat, iz katerega se pripravi raztopina za infundiranje (kapalna infuzija v veno).
It contains the active substance panitumumab.
Vsebuje zdravilno učinkovino panitumumab.
Vectibix is used to treat metastatic carcinoma of the colon or rectum.
Zdravilo Vectibix se uporablja za zdravljenje metastatskega raka kolona ali danke.
This is cancer of the lower intestine (large bowel) that has spread to other parts of the body.
To je rakavo obolenje zadnjega dela črevesa (debelo črevo), ki se je razširilo na druge dele telesa.
Vectibix is used on its own in patients whose tumour cells have a protein on their surface called the epidermal growth factor receptor (EGFR) and which contain a non-mutated ‘ KRAS’.
Zdravilo Vectibix se uporablja samostojno pri bolnikih, katerih tumorske celice imajo na svoji površini beljakovino, imenovano receptor za epidermalni rastni dejavnik (EGFR), in ki vsebujejo nemutirani „ KRAS “.
KRAS is a gene that, when mutated in tumour cells, stimulates tumour growth.
KRAS je gen, ki po mutaciji v tumorski celici spodbuja rast tumorja.
Vectibix is used after treatment with combinations of anticancer medicines that include a ‘ fluoropyrimidine’ (such as 5-fluorouracil), oxaliplatin and irinotecan has stopped working.
Zdravilo Vectibix se uporablja potem, ko je zdravljenje s kombinacijami zdravil proti raku, ki vključujejo fluoropirimidin (kot je 5- fluorouracil), oksaliplatin in irinotekan, postalo neučinkovito.
Treatment with Vectibix should be supervised by a doctor who has experience in the use of anticancer therapy.
Zdravljenje z zdravilom Vectibix mora nadzorovati zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje rakavih obolenj.
It should only be started once detection of non-mutated KRAS has been performed by an experienced laboratory using a reliable method.
Zdravljenje z njim se sme začeti šele potem, ko je bil v izkušenem laboratoriju z zanesljivo metod ugotovljen nemutiranega gena KRAS.
The recommended dose of Vectibix is 6 mg per kilogram body weight given once every two weeks as an infusion.
Priporočeni odmerek zdravila Vectibix znaša 6 mg na kilogram telesne mase, daje pa se ga enkrat na dva tedna v obliki infuzije.
The recommended infusion time is around 60 minutes, but larger doses may need 90 minutes.
Priporočeni čas infundiranja znaša približno 60 minut, pri večjih odmerkih pa bo morda potrebnih 90 minut.
A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and bind to a specific structure (called an antigen) that is found on certain cells in the body.
Monoklonsko protitelo je protitelo (vrsta beljakovine), ki je bilo zasnovano tako, da prepozna specifično strukturo (imenovano antigen), ki se nahaja na določenih celicah v telesu, in se veže nanjo.
Panitumumab has been designed to bind to EGFR, which can be found on the surface of certain cells, including cells in some tumours.
Panitumumab je bil zasnovan tako, da se veže na EGFR, ki ga je mogoče najti na površini določenih celic, vključno s celicami pri nekaterih tumorjih.
As a result of this binding, these tumour cells can no longer receive the messages transmitted via EGFR that they need for growth, progression and spreading (metastasis).
Zaradi vezave te tumorske celice ne morejo nič več sprejemati sporočil, ki se prenašajo preko EGFR in jih potrebujejo za svojo rast, napredovanje in razširjanje (metastaze).
Panitumumab does not seem to work in tumour cells that contain mutated KRAS.
Zdi se, da panitumumab ne deluje pri tumorskih celicah, ki vsebujejo mutirani gen KRAS.
This is because their growth is not controlled by signals transmitted via EGFR and they continue to grow even when the EGFR is blocked.
Razlog za to je, ker njihove rasti ne nadzorujejo signali, ki se prenašajo prek EGFR, zato še naprej rastejo, tudi kadar je EGFR blokiran.
The effects of Vectibix were first tested in experimental models before being studied in humans.
Učinki zdravila Vectibix so bili najprej preizkušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
Vectibix has been studied in one main study involving a total of 463 patients with colon and rectum cancer whose disease had got worse during or after previous treatment that included a fluoropyrimidine, oxaliplatin and irinotecan.
Zdravilo Vectibix so proučevali v eni glavni študiji, v kateri je skupno sodelovalo 463 bolnikov z rakom kolona in danke, pri katerih se je bolezen poslabšala med predhodnim zdravljenjem s fluoropirimidinom, oksaliplatinom in irinotekanom ali po njem.
The effects of Vectibix in addition to ‘ best supportive care’ were compared with those of best supportive care alone.
Učinke zdravila Vectibix skupaj z „ najboljšo podporno oskrbo “ so primerjali z učinki najboljše podporne nege same.
Best supportive care is any medicines or techniques to help patients, such as antibiotics, painkillers, transfusions and surgery, but not other anticancer medicines.
Najboljša podporna nega pomeni katera koli zdravila ali tehnike, ki so bolnikom v pomoč, kot so na primer antibiotiki, zdravila proti bolečinam, transfuzije in kirurški posegi, ne pa druga zdravila za zdravljenje rakavih obolenj.
The main measure of effectiveness was the time taken before the disease started to get worse or the patient died.
Glavno merilo učinkovitosti je bil čas, ki je minil, preden se je bolezen začela slabšati ali pa je bolnik umrl.
The results of the study were analysed separately in 243 patients whose tumours contained KRAS that had not mutated and in 184 patients in whom the KRAS gene contained a mutation.
Rezultate te študije so analizirali ločeno pri 243 bolnikih, pri katerih so tumorji vsebovali gen KRAS, ki ni mutiral, in pri 184 bolnikih, pri katerih je gen KRAS vseboval mutacijo.
In the patients with non-mutated KRAS in their tumours, Vectibix prolonged the time until the disease got worse or the patient died: this took an average of 12.3 weeks in the patients who took Vectibix in addition to best supportive care, compared with 7.3 weeks in those who received best supportive care alone.
Za to je bilo v povprečju potrebnih 12, 3 tedna pri bolnikih, ki so jemali zdravilo Vectibix poleg najboljše podporne nege, v primerjavi s 7, 3 tedna pri tistih bolnikih, ki so bili deležni le najboljše podporne nege same.
In contrast, there was no effect of Vectibix in the patients with mutated KRAS in their tumours, with an average time of around 7.3 weeks until disease progression or death in both groups of patients.
V nasprotju s tem pa niso ugotovili nobenega učinka zdravila Vectibix pri bolnikih z mutiranim genom KRAS v njihovih tumorjih, povprečni čas, ki je potekel do napredovanja bolezni ali smrti pri obeh skupinah bolnikov pa je znašal približno 7, 3 tedna.
What is the risk associated with Vectibix?
Kakšna tveganja so povezana z uporabo zdravila Vectibix?
Around 90% of patients receiving Vectibix have side effects affecting the skin, although most of these are mild or moderate.
Pri približno 90% bolnikov, ki so prejemali zdravilo Vectibix, so se pojavili neželeni učinki, ki so prizadeli kožo, čeprav je bila večina od teh učinkov blagih ali zmernih.
The most common side effects with Vectibix (seen in more than 1 patient in 10) are rash, erythema (redness of the skin), skin exfoliation (skin flaking), pruritus (itching), dry skin, skin fissures (cracks in the skin), paronychia (nail bed infection), diarrhoea, fatigue (tiredness), nausea (feeling sick), vomiting, dyspnoea (difficulty breathing) and cough.
Najpogostejši neželeni učinki pri uporabi zdravila Vectibix (opaženi pri več kot 1 bolniku izmed 10) so izpuščaji, eritem (pordelost kože), eksfoliacija kože (luščenje koža), pruritus (srbenje), suha koža, fisure na koži (razpoke na koži), zanohtnica (okužba nohtne posteljice), driska, utrujenost, navzeja (slabost), bruhanje, dispneja (oteženo dihanje) in kašelj.
For the full list of all side effects reported with Vectibix, see the Package Leaflet.
Za celoten seznam vseh neželenih učinkov, o katerih so poročali pri uporabi zdravila Vectibix, glejte navodilo za uporabo.
Vectibix should not be used in people who may be hypersensitive (allergic) to panitumumab or any of the other ingredients.
Zdravila Vectibix ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) panitumumab ali katero koli drugo sestavino zdravila.
It should also not be used in patients with interstitial pneumonitis or pulmonary fibrosis (lung diseases).
Prav tako se ne sme uporabljati pri bolnikih z intersticijskim pnevmonitisom ali pljučno fibrozo (obolenjem pljuč).
The Committee for Medicinal Products for Human Use (CHMP) concluded that Vectibix’ s benefits are greater than its risks as monotherapy for the treatment of patients with EGFR expressing metastatic colorectal carcinoma with non-mutated (wild-type) KRAS after failure of fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy regimens.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Vectibix, ki se kot samostojno zdravilo uporablja pri zdravljenju bolnikov z metastaskim kolorektalnim rakavim obolenjem, pri katerih je izražen EGFR in imajo nemutirani (divji tip) gena KRAS, potem ko zdravljenje s kemoterapevtskimi sredstvi, ki vsebujejo fluoropirimidin, oksaliplatin in irinotekan, ni več učinkovito, večje od z njim povezanih tveganj.
The Committee recommended that Vectibix be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Vectibix odobri dovoljenje za promet.
Vectibix has been given ‘ Conditional Approval’.
Za zdravilo Vectibix je bila sprejeta „ pogojna odobritev “.
This means that there is more evidence to come about the medicine, in particular its safety and effectiveness in patients whose tumours contain non-mutated KRAS.
To pomeni, da pričakujemo še več dokazov o zdravilu, zlasti o njegovi varnosti in učinkovitosti pri bolnikih, pri katerih tumorji vsebujejo nemutirani gen KRAS.
What information is still awaited for Vectibix?
Katere informacije o zdravilu Vectibix je treba še pridobiti?
The company that makes Vectibix will supply the results of additional studies looking at the safety and effectiveness of the medicine in patients with colorectal cancer with and without mutated KRAS, as well as at the quality of life in patients receiving it.
Družba, ki izdeluje zdravilo Vectibix, bo priskrbela rezultate dodatnih študij, v katerih se preverja varnost in učinkovitost zdravila pri bolnikih s kolorektalnim rakom z mutiranim genom KRAS in brez njega kot tudi kakovost življenja bolnikov, ki so zdravilo prejemali.
These include studies looking at the use of Vectibix in combination with other medicines, both in patients whose disease has been treated before and in patients who have not received any previous treatment for their cancer, as well as a study to confirm the effectiveness of Vectibix, given on its own, in its approved use.
Pri tem bodo vključene tudi študije uporabe zdravila Vectibix skupaj z drugimi zdravili pri bolnikih, pri katerih so bolezen zdravili že prej, in pri bolnikih, katerih rak še ni bil zdravljen, ter študija za potrditev učinkovitosti zdravila Vectibix, ki se daje samostojno v okviru odobrene uporabe.
The European Commission granted a marketing authorisation valid throughout the European Union for Vectibix to Amgen Europe B. V. on 3 December 2007.
Evropska komisija je dovoljenje za promet z zdravilom Vectibix, veljavno po vsej Evropski uniji, odobrila družbi Amgen Europe B. V. dne 3. decembra 2007.
The full EPAR for Vectibix can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Vectibix je na voljo tukaj.
Pharmaceutical
zaščiteno ime
Route of
vsebina
administration
farmacevtska oblika
Vectibix 20 mg/ ml concentrate for solution for infusion.
Vectibix 20 mg/ ml koncentrat za raztopino za infundiranje
Each ml of concentrate contains 20 mg panitumumab.
1 mililiter koncentrata vsebuje 20 mg panitumumaba.
Each vial contains either 100 mg of panitumumab in 5 ml, 200 mg in 10 ml, or 400 mg in 20 ml.
1 viala vsebuje 100 mg panitumumaba v 5 ml, 200 mg v 10 ml ali 400 mg v 20 ml.
When prepared according to the instructions given in section 6.6, the final panitumumab concentration should not exceed 10 mg/ ml.
Če je zdravilo pripravljeno po navodilih, navedenih v poglavju 6. 6, končna koncentracija panitumumaba ne sme preseči 10 mg/ ml.
Panitumumab is a human monoclonal IgG2 antibody produced in a mammalian cell line (CHO) by recombinant DNA technology.
Panitumumab je humano monoklonsko protitelo IgG2, pridobljeno v celični liniji sesalskih celic (CHO) s tehnologijo rekombinantne DNA.
Each ml of concentrate contains 0.150 mmol sodium, which is 3.45 mg sodium.
1 mililiter koncentrata vsebuje 0, 150 mmol natrija, kar je 3, 45 mg natrija.
Colourless solution that may contain visible amorphous panitumumab particles.
Brezbarvna raztopina, ki lahko vsebuje vidne amorfne delce panitumumaba.
Vectibix is indicated as monotherapy for the treatment of patients with EGFR expressing metastatic colorectal carcinoma with non-mutated (wild-type) KRAS after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
Vectibix je indiciran kot monoterapija za zdravljenje bolnikov z metastatskim kolorektalnim karcinomom z eksprimiranim EGFR (epidermal growth factor receptor) in nemutiranim (divjim tipom) KRAS po neuspehu shem kemoterapije, ki so vključevale fluoropirimidin, oksaliplatin oz. irinotekan.
Vectibix treatment should be supervised by a physician experienced in the use of anti-cancer therapy.
Zdravljenje z Vectibixom mora nadzirati zdravnik, izkušen v uporabi terapije proti raku.
Detection of non-mutated KRAS expression should be performed by an experienced laboratory using a validated test method.
Ekspresijo nemutiranega KRAS mora ugotoviti izkušen laboratorij in z validirano testno metodo.
The recommended dose of Vectibix is 6 mg/ kg of bodyweight given once every two weeks.
Priporočeni odmerek Vectibixa je 6 mg/ kg telesne mase enkrat na dva tedna.
Prior to infusion, Vectibix should be diluted in 0.9% sodium chloride injection to a final concentration not to exceed 10 mg/ ml (for preparation instructions see section 6.6).
Pred infundiranjem je treba Vectibix razredčiti z 0, 9% raztopino natrijevega klorida za injiciranje na končno koncentracijo; ta ne sme preseči 10 mg/ ml (navodila za pripravo so navedena v poglavju 6. 6).
Vectibix must be administered as an intravenous (IV) infusion via an infusion pump, using a low protein binding 0.2 or 0.22 micrometer in-line filter, through a peripheral line or indwelling catheter.
Vectibix morate aplicirati v intravenski (i. v.) infuziji z infuzijsko črpalko in uporabo 0, 2 - ali 0, 22- mikrometrskega linijskega filtra z majhno vezavo beljakovin, in sicer skozi periferen venski kanal ali stalni kateter.
Doses higher than 1000 mg should be infused over approximately 90 minutes (for handling instructions, see section 6.6).
Odmerke nad 1000 mg je treba infundirati približno 90 minut (za navodila za ravnanje glejte poglavje 6. 6).
The infusion line should be flushed with sodium chloride solution before and after Vectibix administration to avoid mixing with other medicinal products or IV solutions.
Infuzijsko linijo morate pred aplikacijo Vectibixa in po njej sprati z raztopino natrijevega klorida, da boste preprečili mešanje z drugimi zdravili ali intravenskimi raztopinami.
Do not administer as an IV push or bolus.
Zdravila ne smete injicirati z intravenskim vbrizganjem oz. v bolusu.
2 Special populations
2 Posebne populacije
The safety and efficacy of Vectibix have not been studied in patients with renal or hepatic impairment.
Pri bolnikih z okvaro ledvic ali jeter varnost in učinkovitost Vectibixa nista raziskani.
Dose adjustment is not required in the elderly.
Pri starejših odmerka ni treba prilagoditi.
In clinical studies no overall differences in safety or efficacy were observed between patients aged ≥ 65 years and younger patients.
V kliničnih študijah v celoti niso ugotovili razlik v varnosti in učinkovitosti med bolniki, starimi ≥ 65 let, in mlajšimi.
There is no experience in children and Vectibix should not be used in those patients less than 18 years of age.
Vectibixa naj ne bi uporabljali pri bolnikih, mlajših od 18 let.
Patients with interstitial pneumonitis or pulmonary fibrosis (see Section 4.4).
4. 3 Kontraindikacije
Dermatologic related reactions, a pharmacologic effect observed with epidermal growth factor receptor (EGFR) inhibitors, are experienced with nearly all patients (approximately 90%) treated with Vectibix (see section 4.8), the majority are mild to moderate in nature.
Večina reakcij je blagih do zmernih.
If a patient develops dermatologic reactions that are grade 3 (NCI-CTC/ CTCAE) or higher, or that are considered intolerable, temporarily withhold Vectibix administration until the reactions have improved (≤ grade 2).
Če se pri bolniku pojavijo dermatološke reakcije 3. ali višje stopnje (po NCI- CTC/ CTCAE) ali dermatološke reakcije, ocenjene kot neznosne, morate uporabo Vectibixa začasno prekiniti, dokler se reakcije ne izboljšajo (na ≤ 2. stopnjo).
Once improved to ≤ grade 2, reinstate Vectibix administration at 50% of the original dose.
Ko se izboljšajo na ≤ 2. stopnjo, ponovno uvedite Vectibix v odmerku, ki znaša 50% prvotnega odmerka.
If reactions do not recur, escalate the dose of Vectibix by 25% increments until the recommended dose is reached.
Če se reakcije ne ponovijo, povečujte odmerek Vectibixa po 25%, dokler ne dosežete priporočenega odmerka.
If reactions do not resolve (to ≤ grade 2) after withholding 1 or 2 doses of Vectibix, or if reactions recur or become intolerable at 50% of the original dose, the use of Vectibix should be permanently discontinued.
Če se reakcije po izpustitvi 1 ali 2 odmerkov Vectibixa ne umirijo (do ≤ 2. stopnje), ali se ob 50% prvotnega odmerka ponovijo ali postanejo neznosne, morate uporabo Vectibixa trajno prekiniti.
In clinical studies, subsequent to the development of severe dermatological reactions (including stomatitis), infectious complications including sepsis, in rare cases leading to death, and local abscesses requiring incisions and drainage were reported.
V kliničnih študijah so po pojavu hudih dermatoloških reakcij (vključno s stomatitisom) zabeležili infekcijske zaplete, vključno s sepso, ki so v redkih primerih povzročili smrt, ter lokalne abscese, ki so potrebovali incizijo in drenažo.
Patients who have severe dermatologic reactions or who develop worsening reactions whilst receiving Vectibix should be monitored for the development of inflammatory or infectious sequelae, and appropriate treatment promptly initiated.
Bolnike s hudimi dermatološkimi reakcijami ali poslabšanjem reakcij med uporabo Vectibixa morate nadzirati glede vnetnih ali infekcijskih posledic ter nemudoma uvesti ustrezno zdravljenje, če se pojavijo.
It is recommended that patients wear sunscreen and hats and limit sun exposure whilst receiving Vectibix and experiencing rash/ dermatological toxicities, as sunlight can exacerbate any skin reactions that may occur.
Priporočljivo je, da bolniki kožo zavarujejo s sredstvi za sončenje, nosijo klobuke in omejijo izpostavljenost soncu, medtem ko dobivajo Vectibix in imajo osip ali dermatološke toksične učinke.
As Interstitial Lung Disease (ILD) has been observed with EGFR inhibitors, in the event of acute onset or worsening pulmonary symptoms, Vectibix treatment should be interrupted and a prompt investigation of these symptoms should occur.
Zato morate v primeru akutnega nastanka ali poslabšanja pljučnih simptomov zdravljenje z Vectibixom prekiniti in simptome takoj raziskati.
If pneumonitis or lung infiltrates are diagnosed, Vectibix should be discontinued and the patient should be treated appropriately.
Če diagnosticirate pnevmonitis ali pljučne infiltrate, morate zdravljenje z Vectibixom prekiniti in bolnika ustrezno zdraviti.
Patients should be periodically monitored for hypomagnesaemia and accompanying hypocalcaemia prior to initiating Vectibix treatment, and periodically thereafter for up to 8 weeks after the completion of treatment (see section 4.8).
Bolnike je treba pred uvedbo zdravljenja z Vectibixom, redno med zdravljenjem in še 8 tednov po končanem zdravljenju kontrolirati glede hipomagneziemije in spremljajoče hipokalciemije (glejte poglavje 4. 8).
3 Other electrolyte disturbances, including hypokalaemia, have also been observed.
3 Opažali so tudi druge elektrolitske motnje, vključno s hipokaliemijo.
Repletion of these electrolytes is also recommended, as appropriate.
Priporočljivo je tudi dodajanje teh elektrolitov, kot je ustrezno.
This medicinal product contains 0.150 mmol sodium (which is 3.45 mg sodium) per ml of concentrate.
Zdravilo vsebuje manj kot 0, 150 mmol natrija (kar je 3, 45 mg natrija) na mililiter koncentrata.
Vectibix in combination with IFL
Vectibix v kombinaciji z IFL
Patients receiving Vectibix in combination with the IFL regimen [bolus 5-fluorouracil (500 mg/ m2), leucovorin (20 mg/ m2) and irinotecan (125 mg/ m2)] experienced a high incidence of severe diarrhoea (see section 4.8), therefore administration of Vectibix in combination with IFL should be avoided (see section 4.5).
Zato se je treba uporabi Vectibixa v kombinaciji z IFL izogibati (glejte poglavje 4. 5).
Vectibix in combination with bevacizumab and chemotherapy regimens
Vectibix v kombinaciji z bevacizumabom in shemami kemoterapije
A randomized, open-label, multicentre study of 1,053 patients evaluated the efficacy of bevacizumab and oxaliplatin- or irinotecan-containing chemotherapeutic regimens with and without Vectibix in the first-line treatment of metastatic colorectal cancer.
Randomizirana, odprta, multicentrična študija 1. 053 bolnikov je raziskala učinkovitost bevacizumaba ter kemoterapije, ki vključuje oksaliplatin ali irinotekan, z Vectibixom in brez njega kot terapije prve izbire pri metastatskem kolorektalnem raku.
In an interim analysis based on 947 randomized patients, shortened progression free survival time and increased deaths were observed in the patients receiving Vectibix in combination with bevacizumab and chemotherapy.
Vmesna analiza na podlagi podatkov 947 randomiziranih bolnikov je pokazala krajši čas preživetja brez napredovanja in več smrti med bolniki, ki so dobivali Vectibix v kombinaciji z bevacizumabom in kemoterapijo.
A greater frequency of pulmonary embolism, infections (predominantly of dermatologic origin), diarrhoea, and dehydration was also observed in the treatment arms using Vectibix in combination with bevacizumab and chemotherapy.
V terapevtskih krakih z Vectibixom, uporabljenim v kombinaciji z bevacizumabom in kemoterapijo, so bile pogostejše tudi pljučna embolija, okužbe (pretežno dermatološkega izvora), driska in dehidracija.